Added to YB: 2025-07-29
Pitch date: 2025-07-25
ATYR [bullish]
aTyr Pharma, Inc.
-87.16%
current return
Author Info
No bio for this author
Company Info
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Market Cap
$73.8M
Pitch Price
$6.04
Price Target
20.00 (+2479%)
Dividend
N/A
EV/EBITDA
0.06
P/E
-0.89
EV/Sales
-22.27
Sector
Biotechnology
Category
growth
Atyr Pharma Pivotal Pre-Ramble
ATYR: Pulmonary sarcoidosis drug efzofitimod shows promising P2 results with dose-dependent PRO/KSQ-L improvements, biomarker benefits & low relapse rates at therapeutic doses. P3 readout in Q3 with steroid reduction primary endpoint. Risk in novel indication/design, but good steroid reduction anecdotes. 60-70% success probability. $4B potential on win, -95% on failure.
Read full article (12 min)